Pharmaceutical Composition for the Treatment of Solar Urticaria
We offer a lidocaine/prilocaine combination for the treatment or prevention of solar urticaria. Up to now the lidocaine/prilocaine combination is used for dermal anesthesia (marketed as EMLA®). The inventors demonstrated in two of two patients with solar urticaria and an action spectrum to UVA that the combination of lidocaine and prilocaine protects the tissue and inhibits triggering of the cascade which usually leads to typical symptoms of solar urticaria.
The topical application of a lidocaine/prilocaine mixture prior to UV-provocation stabilizes or inhibits sensory nerve fibres of the skin and induces down-regulation or inhibition of the release of pro-inflammatory neuropeptides. Due to this more general concept it is assumed that (1) other local anesthetics in addition to lidocaine and prilocaine, (2) lidocaine alone or prilocaine alone, and (3) lidocaine and/or prilocaine in combination with other local anesthetics are effective as well.
Further Information: PDF
ipal GmbH
Phone: +49 (0)30/2125-4820
Contact
Ursula Haufe
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Properties of new materials for microchips
… can now be measured well. Reseachers of Delft University of Technology demonstrated measuring performance properties of ultrathin silicon membranes. Making ever smaller and more powerful chips requires new ultrathin…
Floating solar’s potential
… to support sustainable development by addressing climate, water, and energy goals holistically. A new study published this week in Nature Energy raises the potential for floating solar photovoltaics (FPV)…
Skyrmions move at record speeds
… a step towards the computing of the future. An international research team led by scientists from the CNRS1 has discovered that the magnetic nanobubbles2 known as skyrmions can be…
